Table.
Characteristics of the study population by vaccination status and immunosuppression
|
Immunocompetent (n=162 805)* |
Immunosuppressed (n=5609)* |
||||
|---|---|---|---|---|---|
| Unvaccinated (n=34 430) | Vaccinated (n=128 375) | Unvaccinated (n=746) | Vaccinated (n=4863) | ||
| Age, years | |||||
| Median (IQR) | 39 (28–54) | 51 (35–65) | 48 (35–59) | 59 (44–69) | |
| ≤30 | 10 928 (32%) | 23 695 (18%) | 130 (17%) | 457 (9%) | |
| 31–50 | 12 968 (38%) | 39 882 (31%) | 289 (39%) | 1202 (25%) | |
| 51–64 | 6581 (19%) | 32 421 (25%) | 217 (29%) | 1458 (30%) | |
| ≥65 | 3953 (11%) | 32 377 (25%) | 110 (15%) | 1746 (36%) | |
| Date of second vaccine dose | NA | April 10 (March 7–April 30) | NA | April 7 (March 13–April 27) | |
| Date of third vaccine dose | NA | Nov 18 (Oct 25–Dec 15) | NA | Oct 28 (Sept 13–Dec 4) | |
| Sex* | |||||
| Male | 14 730 (43%) | 53 649 (42%) | 280 (38%) | 1820 (37%) | |
| Female | 19 700 (57%) | 74 726 (58%) | 466 (62%) | 3043 (63%) | |
| Race* | |||||
| White | 25 389 (74%) | 99 934 (78%) | 574 (77%) | 3919 (81%) | |
| Black | 5008 (15%) | 10 305 (8%) | 122 (16%) | 536 (11%) | |
| Asian | 2454 (7%) | 13 411 (10%) | 17 (2%) | 251 (5%) | |
| American Indian or Alaska Native | 146 (<1%) | 389 (<1%) | 5 (1%) | 18 (<1%) | |
| Native Hawaiian and other Pacific Islander | 34 (<1%) | 118 (<1%) | 1 (<1%) | 3 (<1%) | |
| Other | 1399 (4%) | 4218 (3%) | 27 (4%) | 136 (3%) | |
| Number of previous negative SARS-CoV-2 tests | |||||
| 0 | 26 938 (78%) | 83 083 (65%) | 346 (46%) | 1940 (40%) | |
| 1 | 4752 (14%) | 25 627 (20%) | 151 (20%) | 1085 (22%) | |
| 2–4 | 2389 (7%) | 16 978 (13%) | 184 (25%) | 1311 (27%) | |
| ≥5 | 351 (1%) | 2687 (2%) | 65 (9%) | 527 (11%) | |
| Weighted comorbidity index† | |||||
| 0 | 31 905 (93%) | 107 976 (84%) | 449 (60%) | 2194 (45%) | |
| 1–2 | 2010 (6%) | 15 648 (12%) | 222 (30%) | 1799 (37%) | |
| 3–4 | 315 (1%) | 3068 (2%) | 49 (7%) | 478 (10%) | |
| ≥5 | 200 (1%) | 1683 (1%) | 26 (3%) | 392 (8%) | |
| Immunosuppressant medication type | |||||
| None | 34 430 (100%) | 128 375 (100%) | NA | NA | |
| Glucocorticoid | NA | NA | 290 (39%) | 1681 (35%) | |
| Immunosuppressive DMARD | NA | NA | 240 (32%) | 1612 (33%) | |
| Immunomodulatory DMARD | NA | NA | 100 (13%) | 784 (16%) | |
| Multiple types | NA | NA | 116 (16%) | 786 (16%) | |
| Previous bone marrow or organ transplantation‡ | 41 (<1%) | 355 (<1%) | 80 (11%) | 496 (10%) | |
| Number of hospital visits§ | 2 (0–7) | 6 (3–13) | 15 (7–30) | 19 (10–36) | |
| SARS-CoV-2 infection¶ | 872 (3%) | 3058 (2%) | 73 (10%) | 242 (5%) | |
| COVID-19-related hospitalisation | 62 (<1%) | 94 (<1%) | 20 (3%) | 27 (1%) | |
Data are n (%) or median (IQR). NA=not applicable. DMARD=disease-modifying antirheumatic drug.
Table shows participants with complete data after excluding those with missing covariates.
Comorbidity index was calculated using diagnosis codes reported within the 18 months before Dec 16, 2021.
Transplantation status determined on the basis of the presence of International Classification of Diseases-10 code Z94 within the 12 months before Dec 16, 2021.
Number of visits was defined as the number of in-person hospital visits for the patient within the 18 months before Dec 16, 2021.
SARS-CoV-2 infections and COVID-19-related hospitalisations for vaccinated individuals are listed as long as they occurred during the study period, regardless of whether they occurred before vaccination, after partial vaccination, or after full vaccination.